Cancer treatments can lead to unpredictable adverse events, so a COVID-19–related measure allowing home infusion jeopardizes patient health and safety, according to the Community Oncology Alliance (COA).
Patient safety might be compromised because of home infusion regulatory changes brought about by the coronavirus disease 2019 (COVID-10) pandemic, according to the Community Oncology Alliance (COA), although other groups support the changes, which affect Medicare Part B beneficiaries.
The virus has altered healthcare not just for those with the novel virus, but also for patients with cancer or rare diseases. Providers are working overtime to accommodate the sudden need.
CMS has allowed numerous workforce changes to increase the capabilities and ranks of frontline healthcare workers during this emergency. In an additional change, added Thursday, CMS allowed doctors to work across state lines and nurse practitioners to perform medical exams in nursing homes.
Many providers are pleased with these new flexibilities, which include the use of telehealth.
CMS has also temporarily relaxed standards for home infusion therapy, physician contracts, remote monitoring, and coverage determinations
Last week, COA said of the health of patients with cancer could be jeopardized by some of these changes. COA said it opposes home infusion of chemotherapy, cancer immunotherapy, and supportive drugs related to cancer.
Home infusion “by a provider who may not be a trained oncology nurse and may not recognize or be prepared to treat any of the serious adverse reactions that frequently occur is of significant concern,” COA said, adding that many of the adverse events related to cancer treatment cannot be adequately monitored if patients are self-administering at home.
Visit AJMC.com for the full story.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.